Comparative Pharmacology
Head-to-head clinical analysis: NILOTINIB HYDROCHLORIDE DIHYDRATE versus RETEVMO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NILOTINIB HYDROCHLORIDE DIHYDRATE versus RETEVMO.
NILOTINIB HYDROCHLORIDE DIHYDRATE vs RETEVMO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nilotinib is a BCR-ABL tyrosine kinase inhibitor that binds to and stabilizes the inactive conformation of the ABL kinase domain, thereby inhibiting proliferation and inducing apoptosis in Philadelphia chromosome-positive (Ph+) leukemic cells.
RETEVMO (selpercatinib) is a potent and selective RET kinase inhibitor. It inhibits wild-type RET and multiple RET fusions (e.g., KIF5B-RET, CCDC6-RET) and mutations (e.g., M918T, C634W, V804M/L/E) by binding to the ATP-binding site of RET, blocking downstream signaling pathways including MAPK/ERK and PI3K/AKT, thereby inhibiting tumor cell proliferation.
400 mg orally twice daily, approximately 12 hours apart, without food (at least 2 hours before or 1 hour after a meal).
160 mg orally twice daily
None Documented
None Documented
Approximately 17 hours (terminal elimination half-life; supports once-daily or twice-daily dosing; extensive accumulation with daily dosing, steady state by day 8)
18 hours (terminal elimination half-life) supporting twice-daily dosing; steady-state reached within ~3 days.
Fecal (93%), renal (3%; unchanged nilotinib appears minimal, mostly metabolites)
Primarily biliary/fecal (approximately 75% of administered dose recovered in feces as unchanged drug and metabolites); renal elimination accounts for <10% (mostly metabolites).
Category D/X
Category C
Kinase Inhibitor
Kinase Inhibitor